Less than a year after emerging from stealth, Danish-based QuantumCell has signed a multi-billion-dollar deal to equip its pipeline with Alzheimer’s drug technology.
The biotech has entered into a licensing and collaboration agreement with Swedish company AlzeCure Pharma for rights to the latter’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. QuantumCell is paying only $12m upfront, but a tail-heavy weighting to the deal with milestone payments means the total transaction could exceed $2.2bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The upfront fee itself also includes a $5m direct investment in AlzeCure, at a 30% premium to AlzeCure’s average share price over the last 10 trading days.
NeuroRestore develops small-molecule drugs designed to improve cognitive functions, like learning and memory, in patients with cognitive disorders, though its primary focus is currently Alzheimer’s disease.
ACD856 is a small-molecule positive modulator of both NGF/TrkA and BDNF/TrkB mediated signalling (Trk-PAM). Trk receptors are located on neurons and are critical for synaptic strength and plasticity. According to AlzeCure, ACD856 has already shown neuroprotective, anti-inflammatory and disease-modifying effects in several preclinical models.
In Phase Ib data published in June 2026, ACD856 was safe and well-tolerated when given repeatedly at higher doses than previously tested. At the time, AlzeCure’s chief medical officer Märta Segerdahl said: “An expected increase in the concentration of ACD856 was seen in both blood and cerebrospinal fluid. These data further strengthen the continued development of ACD856, broaden the therapeutic window, and provide a solid foundation for dose selection in future clinical studies.”
QuantumCell has not revealed the indications it plans to pursue with ACD856. Indeed, the biotech has kept much of its business strategy and R&D in the shadows.
QuantumCell emerged onto the biotech scene in December 2025 with backing from Lundbeckfonden and Novo Holdings. Its high-profile venture capital investors hint at how the biotech was able to strike such a large deal relatively early on in its lifecycle.
On its LinkedIn page, the company describes itself as a “dynamic biology company on a mission to decode and defeat the most complex brain disorders of our time. By converging next-generation sensing technologies, autonomous robotics, and cutting-edge AI, we are building the world’s first high-fidelity virtual cell and virtual system model: a mechanistically anchored simulation of human biology that can predict how drugs will behave in a patient before a single trial is run.”
The QuantumCell marks the second out-licensing transaction by AlzeCure this year. In June, Eli Lilly outlaid up to $1bn to secure rights to the Swedish pharma’s ACD680, another candidate in development for the treatment of Alzheimer’s.
